Events7th International Electronic Conference on Medicinal Chemistry
Published
This submission belongs to the session S4. Fighting cancers of the event 7th International Electronic Conference on Medicinal Chemistry
Published date
03 Nov, 2021
Academic Editor
author-avatarJean Jacques Vanden Eynde
Citation
Akshita Chauhan, Tabassum Khan, Synthesis of kinase inhibitors as anti-cancer agents, in Proceedings of 7th International Electronic Conference on Medicinal Chemistry, 1 November–30 November 2021, MDPI: Basel, Switzerland, doi: 10.3390/ECMC2021-11573
Share
Email
Facebook
Twitter
LinkedIn

Synthesis of kinase inhibitors as anti-cancer agents

image
1. Department of Quality Assurance, SVKM’s Dr. Bhanuben Nanavati College of Pharmacy, Mumbai, Maharashtra, India
2. Department of Pharmaceutical Chemistry and Quality Assurance, SVKM’s Dr. Bhanuben Nanavati College of Pharmacy, Mumbai, Maharashtra, India
Abstract

Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase located at the extracellular matrix cell adhesion site. This kinase mediates downstream signalling cascades on the cell-extracellular matrix of integrins, cytokine receptors, growth factor receptors and G-protein-coupled receptors. Several studies have suggested the importance of FAK in cancer cell adhesion, motility, proliferation and survival and is over-expressed in cancer cells. Herein, we report a series quinazolinone-amine analogues (4a-4j) synthesized using conventional and microwave methods. These synthesized analogues were evaluated using MTT assay on MCF-7 and MDA-MB-231 cell lines indicated that analogues have potent cytotoxicity activity. The molecular docking studies on FAK showed that 4h and 4i have maximum binding affinity of -8.9 kcal/mol. This could be attributed to the presence of fluoro (-F) and nitro (-NO2) group. This research work demonstrated the utility of quinazolinone series as potential FAK inhibitors. Analogue 4h emerged as a strong lead that can be developed into a potent FAK inhibitor in cancer therapeutics.

Keywords
Focal adhesion kinase
FAK inhibitor
quinazolinone
cancer therapy
Poster
Poster Presentation.pdf
Pharmacophore-based drug design and synthesis of potential CDK2 inhibitors as anticancer entities
Development of an oral feed additive against intestinal infections based on microparticles’ systems loaded with Ctx(Ile21)-Ha peptide coated with HPMCAS/Chitosan